Results 321 to 330 of about 1,468,461 (396)

T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Background Tumour infiltrating lymphocyte (TIL) T‐cell receptor (TCR) repertoire is prognostic in newly diagnosed diffuse large B‐cell lymphoma (DLBCL), but evolution has not been evaluated at relapse. Methods We examined the TCR repertoire in nine paired DLBCL samples from diagnosis and relapse. Results We noted considerable differences, with
Joel Wight, Tom Witkowski, Colm Keane, Eliza A. Hawkes   +3 more
wiley   +1 more source

Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Despite the good options for the management of Diffuse large B‐cell lymphoma (DLBCL), a significant percentage of patients either do not respond to current treatments or relapse after a short time. Thus, a wider palette of targeted therapeutic strategies is needed.
Abdullah Alraddadi, Joshua P. Smalley, Wael Alzahrani, Anes Saleh, Fares Al‐Mansour, Buwei He, Thong H. Cao, Sandrine Jayne, Martin Dyer, James T. Hodgkinson, Donald J. L. Jones, Shaun M. Cowley, Salvador Macip   +12 more
wiley   +1 more source

Application of Immune Checkpoint Inhibitors in Cancer

MedComm, Volume 6, Issue 8, August 2025.
Immune checkpoint inhibitors (ICIs) revolutionize oncology by harnessing immunity against advanced cancers. This review systematically explores ICI mechanisms, clinical applications in advanced malignancies (e.g., head and neck squamous cell carcinoma, esophageal cancer, non‐small cell lung cancer, breast cancer, hepatocellular carcinoma, and bladder ...
Zhijun Chen, Zihan Song, Shichen Den, Wei Zhang, Mengjia Han, Tianhang Lan, Xiaokang Du, Jingyun Ning, XinHui Chen, Haoming Lin, Rui Zhang   +10 more
wiley   +1 more source

Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies. [PDF]

Appl Microsc
Kim HU, Kim YK.
europepmc   +1 more source

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. [PDF]

Curr Oncol
Fleury I, MacDonald D, Shafey M, Christofides A, Sehn LH.   +4 more
europepmc   +1 more source

Hijacking erythropoietin: A tumour‐intrinsic strategy to escape immune surveillance

Clinical and Translational Medicine, Volume 15, Issue 8, August 2025.
David Kung‐Chun Chiu, Edgar G Engleman
wiley   +1 more source

Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment. [PDF]

Curr Oncol
Khan SR, Breadner D.
europepmc   +1 more source